Transforming complex disease treatment through
science-driven regenerative solutions.
We are a biotechnology company specialising in stem cell–based innovations in oncology and advanced wound healing. Rooted in scientific expertise and inspired by innovation, we are dedicated to transforming how complex diseases are treated. To expand our global research footprint and accelerate the translation of stem cell discoveries into real-world therapies, we have established OCT Biopharma Inc. in Moncton, New Brunswick, as a 100% subsidiary of OCT Therapies and Research Pvt. Ltd.- our India-based parent company.
Our work focuses on harnessing the therapeutic potential of stem cells to develop next-generation solutions for cancer care and tissue repair. By combining rigorous research, cutting-edge technologies, and global scientific collaborations, we aim to accelerate breakthroughs that improve patient outcomes and elevate standards of care.
With our expansion into Canada, we are committed to contributing to Atlantic Canada’s growing life sciences ecosystem while advancing high-impact biomedical research that bridges innovation between India and North America.
Oral mucositis (OM) is a prevalent & distressing side effect of cancer treatment that
significantly impacts patients' well-being, quality of life, and ability to tolerate therapy. In
cancer patients, OM is linked to poor outcomes.

Growth factors & cytokines
play a role in tissue
regeneration.

We are entering into first in-human clinical trials.

Safety Studies
MSC-derived CM gels tested for healing potential and safety in various wound types
Genetic and systemic safety confirmed: MSC-CM non-mutagenic and well-tolerated
Topical MSC-CM effective in chemotherapy and radiation-induced wounds with regeneration
First of its kind topical
self-administration
Cell-free alternative to
transplantation for
chemotherapy and radiation
wound healing
Bio-compatible, safe
and efficacious